Literature DB >> 9076235

Sinonasal melanoma. A clinicopathologic study of 25 cases and literature meta-analysis.

M S Brandwein1, A Rothstein, W Lawson, C Bodian, M L Urken.   

Abstract

OBJECTIVES: To report on 25 cases of sinonasal melanoma at our institution during 1977 to 1995 and to perform a literature meta-analysis on sinonasal melanoma and study survival statistics. DATA SOURCES: A retrospective search of pathology and clinical records at our institution to identify patients with sinonasal melanoma; a retrospective search of the English-language literature for cases of documented sinonasal melanoma. STUDY SELECTION: Cases from our institution were included if there was adequate pathologic material confirming the pathologic diagnosis. For the meta-analysis, cases were accepted if they included convincing histologic illustrations or documentation of melanin by Fontana-Masson staining or ultrastructural examination or had an acceptable immunohistochemical profile with some documented clinical follow-up on individual patients. DATA EXTRACTION: The following parameters were monitored for patients from our institution: age, sex, possible exposure histories, tumor site, tumor size, type of therapy, clinical outcome, cytochemistry (Fontana-Masson stain), and immunohistochemical profile (S-100, HMB-45, vimentin, cytokeratin). The parameters of the meta-analysis were age, sex, tumor site, and survival data. DATA SYNTHESIS: Our patient population included 10 men and 15 women aged 23 to 83 years (mean, 65 years). Tumor sites included inferior turbinate, superior nasal cavity, nasal cavity floor/palate, ethmoid sinuses, and maxillary sinus. The immunohistochemical profile was as follows (positive cases): S-100 (14 of .14), HMB-45 (12 of 14), vimentin (9 of 10), cytokeratin (0 of 9). Melanin was demonstrated by Fontana-Masson stain (8 of 8 cases). Follow-up information was available in 25 cases, with follow-up ranging from 1 to 217 months (mean, 39 months). Eleven patients were disease free at 1 to 217 months (mean, 59 months) after excision. Local single recurrences developed in 6 patients at 3 to 84 months (mean, 14 months), and were treated with surgery. Multiple local recurrences were seen in 2 patients. One of them died of disseminated disease, after 2 local recurrences, 60 months after original diagnosis. The other was disease free after 38 months. Ten patients ultimately died of disease within 2 to 60 months after diagnosis (mean, 21 months). Only 2 patients may have developed metastatic disease in the absence of local recurrence. A total of 163 cases were identified from the literature: 53 women, 54 men (56 gender unknown). Stratification by era (pre-1980 vs post-1980) did not reveal any gender differences (pre-1980: 34 women [48%], 37 men [52%]; post-1980: 34 women [55%], 27 men [44%]). However, stratification by era did reveal an age shift toward older patients in the 1980-1995 era. The 5-year median survival for all patients was 36 months. Stratification by era of treatment revealed a long-term survival trend: patients treated before 1980 had somewhat better survival at 60 and 100 months (40% and 36%, respectively) than patients diagnosed and treated between 1980 and 1995 (30% and 23%, respectively), although statistical significance was not reached.
CONCLUSION: It is unclear why the long-term survival for patients with sinonasal melanoma seems to be decreasing. Despite advances in imaging techniques, which would potentially allow for earlier tumor discovery, and advances in surgical techniques and adjuvant therapeutics, the mean survival for patients with sinonasal melanoma has not improved during the past 15 years.

Entities:  

Mesh:

Year:  1997        PMID: 9076235     DOI: 10.1001/archotol.1997.01900030064008

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  13 in total

1.  Update on pigmented lesions of the sinonasal tract.

Authors:  Manju L Prasad
Journal:  Head Neck Pathol       Date:  2007-10-26

2.  Anterior skull base surgery.

Authors:  Moni Abraham Kuriakose; Nirav P Trivedi; Vikram Kekatpure
Journal:  Indian J Surg Oncol       Date:  2010-11-21

Review 3.  Malignant mucosal melanoma of the head and neck.

Authors:  Erzsébet Lengyel; Katalin Gilde; Eva Remenár; Olga Esik
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

4.  The value of 18F-FDG-PET/CT imaging for sinonasal malignant melanoma.

Authors:  S K Haerle; M B Soyka; D R Fischer; K Murer; K Strobel; G F Huber; D Holzmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-29       Impact factor: 2.503

Review 5.  The skull base, paranasal sinuses, and related malignancies.

Authors:  Chad A Zender; Guy J Petruzzelli
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

6.  Sinonasal mucosal melanoma: a 13-year experience at a single institution.

Authors:  Kailash Narasimhan; Omer Kucuk; Ho-Sheng Lin; Lance K Heilbrun; Michael Carron; Raghu Venkatramanamoorthy; Robert Mathog
Journal:  Skull Base       Date:  2009-07

7.  The evaluation of malignant mucosal melanoma of nasal cavity with a rare occasion.

Authors:  Ahmet H Kepekci; Cenk Kig; Gul I Gundogan
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-08-10

8.  Primary mucosal sinonasal melanoma-Case report and review of the literature. The role of complex treatment-surgery and adjuvant radiotherapy.

Authors:  Lena Marinova; Kaloyan Yordanov; Nikolay Sapundgiev
Journal:  Rep Pract Oncol Radiother       Date:  2010-12-21

9.  Unknown primary nasopharyngeal melanoma presenting as severe recurrent epistaxis and hearing loss following treatment and remission of metastatic disease: A case report and literature review.

Authors:  Saïd C Azoury; Joseph G Crompton; David M Straughan; Nicholas D Klemen; Emily S Reardon; Tatiana H Beresnev; Marybeth S Hughes
Journal:  Int J Surg Case Rep       Date:  2015-04-01

10.  Evaluation of the prognostic impact of postoperative adjuvant radiotherapy on head and neck mucosal melanoma: a meta-analysis.

Authors:  Wei Li; Yalian Yu; Hailong Wang; Aihui Yan; Xuejun Jiang
Journal:  BMC Cancer       Date:  2015-10-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.